Efficacy of High-dose Statins Pretreatment on PCI-related Inflammation and Myocardial Injury

Objective To explore the effect of atorvastat in pretreatment on percutaneous coronary intervention ( PCI )-related inflammation and myocardial injury. Methods Eighty six patients with coronary heart diseases undergoing PCI were randomized into A group (n=30), B group (n=26) and C group (n=30). They were given 20, 80 and 0 mg atorvastatin tablet for 2 days before PCI, respectively. A and C group patients took 20 mg atorvastatin every night after PCI, well the B group took 40 mg per night. The neutrocyte count, the levels of high sensitivity C reactive protein (hs-CRP), enzyme, troponin T (cTnT), liver function, kidney function, blood lipids and electrocardiogram were determined before and after PCI. The incidence of perioperative myocardial infarction (MI) after successful PCI was also recorded. Results The changes of hs- CRP level, neutrocyte count were significant after PCI (P0.05). The degree of △hs-CRP, creatine kinase MB (CK-MB), cTnT elevation in B group was significantly less than that of A and C group (P0.05). Incidence of perioperative MI was lowest in the B group (P0.05). The highest compliance rate of LDL-C postoperative also in the B group (P0.05). The changes of liver and kidney function, creatine kinase were not significant before and after PCI in 3 groups (P0.05). Conculsion Pretreatment with atorvastatin 80 mg for patients under going PCI for 48 hours can inhibit PCI-related inflammation and have a protective effect against myocardial injury. Safety did not differ between high-dose and low-dose atorvastatin.